Divalproex sodium (Depakote)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Migraine, Epilepsy, Absence Seizures, Bipolar Disorder, Focal Onset Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
US
  • Mania Depakote (divalproex sodium) is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. The efficacy of Depakote was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clin
Product first approved 1983Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (22)
Bipolar Disorder
NCT00183443 · Palo Alto Veterans Institute for Research
2005-02 – 2010-11 · Bipolar Disorder, Schizophrenia
What this study did
NCT00057681 · Washington University School of Medicine
2003-02 – 2008-12 · Bipolar Disorder
What this study did
NCT00176202 · University of Illinois at Chicago
2003-04 – 2008-01 · Bipolar Disorder
What this study did
NCT00221975 · University Hospitals Cleveland Medical Center
2002-07 – 2007-12 · Bipolar Disorder
What this study did
NCT00195780 · Abbott
started 2005-02 · Bipolar I Disorder
What this study did
NCT00114686 · AstraZeneca
2006-01 – 2007-04 · Bipolar I Disorder, Alcohol Dependence
What this study did
NCT00195767 · Abbott
started 2004-07 · Bipolar I Disorder, Manic or Mixed
What this study did
NCT00107731 · AstraZeneca
2004-04 – 2006-10 · Bipolar I Disorder
What this study did
NCT00081380 · AstraZeneca
2004-03 – 2006-09 · Bipolar Disorder
What this study did
NCT00060905 · Abbott
started 2003-01 · Bipolar Disorder
What this study did
Epilepsy
NCT00102713 · Abbott
started 2005-02 · Partial Seizures
What this study did
NCT00067431 · Abbott
started 2003-07 · Partial Seizure Disorder
What this study did
Migraine
NCT00195806 · Abbott
started 2005-02 · Migraine
What this study did
Other / comorbidity
NCT00315900 · Tuscaloosa Research & Education Advancement Corporation
2006-05-01 – 2008-02-28 · Agitation, Dementia
What this study did
NCT00278772 · Lindner Center of HOPE
2003-08 – 2007-12 · Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania
What this study did
NCT00108576 · VA Office of Research and Development
2003-10 – 2005-09 · PTSD
What this study did
NCT00218114 · New York State Psychiatric Institute
2000-02 – 2005-02-18 · Attention Deficit and Disruptive Behavior Disorders, Marijuana Abuse
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00202514 · Seattle Institute for Biomedical and Clinical Research
2004-09 – 2006-07 · Alcoholism, Alcohol Related Disorders, Mood Disorders
What this study did
Phase 2 (9)
Epilepsy
NCT00646711 · Abbott
2003-02 – 2003-12 · Pediatric Epilepsy
What this study did
Other / comorbidity
NCT02094651 · Boston Children's Hospital
2014-04 – 2016-10 · Autism
What this study did
NCT01170325 · National Institute of Mental Health (NIMH)
2010-06-30 – 2011-01-28 · Autism, Autism Spectrum Disorders
What this study did
NCT00078754 · University of Chicago
2003-05 – 2008-10 · Intermittent Explosive Disorder
What this study did
NCT00211757 · Montefiore Medical Center
2002-09 – 2008-07 · Autism
What this study did
NCT00073164 · Abbott
started 2003-07 · Schizophrenia
What this study did
NCT00217932 · National Institute on Drug Abuse (NIDA)
2000-09 – 2005-08 · Mood Disorders
What this study did
NCT00088387 · National Institute of Neurological Disorders and Stroke (NINDS)
2004-07 – 2005-03 · Alzheimer Disease
What this study did
NCT00095355 · National Institute of Neurological Disorders and Stroke (NINDS)
2004-10 – 2005-03 · Huntington's Disease
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT03919292 · Virginia Commonwealth University
2019-05-01 – 2031-01-31 · Solid Tumor, Adult
What this study did
NCT02166229 · Yale University
2014-06 – 2014-08 · Scleroderma, Systemic Sclerosis
What this study did
NCT00605657 · Koneti Rao
2008-01 – 2011-09 · ALPS, Hypersplenism, Lymphadenopathy
What this study did
Phase 1 (13)
Epilepsy
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT01898676 · Vince & Associates Clinical Research, Inc.
2013-07 – 2013-12 · Epilepsy
What this study did
Other / comorbidity
NCT01581775 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-03 · Healthy
What this study did
NCT01581788 · Dr. Reddy's Laboratories Limited
2011-01 – 2011-03 · Healthy
What this study did
NCT01056627 · Dr. Reddy's Laboratories Limited
2006-12 – 2007-03 · Healthy
What this study did
NCT01055938 · Dr. Reddy's Laboratories Limited
2006-12 – 2007-03 · Healthy
What this study did
NCT01132183 · Dr. Reddy's Laboratories Limited
2007-02 – 2007-03 · Healthy
What this study did
NCT01132170 · Dr. Reddy's Laboratories Limited
2006-08 – 2006-11 · Healthy
What this study did
NCT01132196 · Dr. Reddy's Laboratories Limited
2006-08 – 2006-11 · Healthy
What this study did
NCT00195156 · Weill Medical College of Cornell University
started 2003-07 · Solid Tumor Malignancies
What this study did
NCT00197834 · Hearthstone Alzheimer Care
started 2004-03 · Dementia
What this study did
NCT00647712 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did
NCT00648076 · Mylan Pharmaceuticals Inc
2004-12 – 2004-12 · Healthy
What this study did
Phase 4 (28)
Bipolar Disorder
NCT01588457 · The University of Texas Health Science Center at San Antonio
2011-06 – 2016-12 · Bipolar I Disorder, Bipolar II Disorder
What this study did
NCT00254488 · Weill Medical College of Cornell University
2005-11 – 2011-08 · Bipolar Disorder, Mania
What this study did
NCT00545142 · Korea Otsuka Pharmaceutical Co., Ltd.
2007-10 – 2010-06 · Bipolar Disorder
What this study did
NCT00183469 · The University of Texas Health Science Center at San Antonio
2004-12 – 2009-04 · Bipolar Disorder, Depression
What this study did
NCT00397020 · University of California, San Diego
2006-12 – 2008-12 · Bipolar Disorder
What this study did
NCT00208195 · Creighton University
2004-03 – 2007-11 · Bipolar Disorder, Mania, Substance Abuse, Substance Dependence
What this study did
NCT00094549 · Eli Lilly and Company
2004-10 – 2006-12 · Bipolar Disorder
What this study did
NCT01075126 · Lawson, William B., M.D., PhD, DFAPA
2006-12 – 2006-12 · Bipolar Disorder
What this study did
NCT00181727 · Massachusetts General Hospital
2004-01 – 2006-11 · Bipolar Disorder, Mania
What this study did
NCT00048802 · Northwell Health
2002-08 – 2006-08 · Bipolar Disorder
What this study did
NCT00226343 · Cambridge Health Alliance
2003-08 – 2006-08 · Bipolar Disorder
What this study did
NCT00221481 · Mayo Clinic
est. completion 2006-03 · Bipolar Disorder
What this study did
NCT00199966 · Medical College of Wisconsin
2003-12 – 2005-11 · Bipolar Disorder
What this study did
NCT00177567 · University of Pittsburgh
2001-07 – 2004-01 · Bipolar Disorder
What this study did
Epilepsy
NCT00207935 · Children's National Research Institute
2005-08 – 2007-03 · Epilepsy, Mental Retardation, Developmental Disabilities
What this study did
NCT00312676 · Veterans Affairs Medical Center, Miami
2006-03 – 2006-10 · Epilepsy, Behavioral Disturbance
What this study did
Other / comorbidity
NCT03012815 · Mayo Clinic
2017-02-01 – 2021-03-01 · Alcohol Withdrawal Syndrome
What this study did
NCT01587066 · Bo-Hyun Yoon
2010-08 – 2011-09 · Bipolar Depression
What this study did
NCT00375557 · University of Cincinnati
2006-10 – 2007-09 · Alzheimer's Disease, Dementia, Behavioral Symptoms
What this study did
NCT00334347 · Massachusetts General Hospital
2006-06 – 2007-09 · Mania, Mixed Mania
What this study did
NCT00208819 · Emory University
2003-09 – 2007-07 · Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
What this study did
NCT00228046 · Stony Brook University
2004-01 – 2007-07 · Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
What this study did
NCT00287053 · Pennington Biomedical Research Center
2006-02 – 2006-10 · Healthy
What this study did
NCT00203385 · Tuscaloosa Research & Education Advancement Corporation
2003-05 – 2005-03 · PTSD
What this study did
NCT00308360 · Nathan Kline Institute for Psychiatric Research
1999-09 – 2004-04 · Schizophrenia
What this study did
NCT02078596 · New York State Psychiatric Institute
1997-03 – 2004-03 · Irritable Aggression
What this study did
Early phase / not applicable (7)
Epilepsy
NCT00318929 · Virginia Commonwealth University
2006-04 – 2008-01 · Elderly, Epilepsy, Seizures
What this study did
NCT00347152 · University of Kansas
2006-11 – 2007-12 · Epilepsy
What this study did
Other / comorbidity
NCT01760785 · University of Colorado, Denver
2008-09 – 2016-06 · Traumatic Brain Injury (TBI), Alcoholism
What this study did
NCT01326663 · Paul Saenger
2009-10 – 2013-12 · Veterans, TBI, Alcoholism, Irritable Mood
What this study did
NCT00203242 · Thomas Jefferson University
2003-07 – 2006-12 · Cluster Headache
What this study did
NCT00552500 · Washington University School of Medicine
2003-02 – 2005-12 · Insulin Resistance, Body Composition
What this study did
NCT00222482 · University of Minnesota
2003-03 – 2005-09 · Borderline Personality Disorder
What this study did
Used as active comparator (10)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (9)
Bipolar Disorder
NCT00913848 · Sandoz
2005-10 – 2005-10 · Epilepsy, Bipolar Disorder
What this study did
NCT00913874 · Sandoz
2005-10 – 2005-10 · Epilepsy, Bipolar Disorder
What this study did
Epilepsy
NCT00864006 · Sandoz
2006-10 – 2006-10 · Seizures
What this study did
Other / comorbidity
NCT01184391 · Mylan Pharmaceuticals Inc
2007-07 – 2007-08 · Healthy
What this study did
NCT01183676 · Mylan Pharmaceuticals Inc
2007-07 – 2007-07 · Healthy
What this study did
NCT00974012 · Teva Pharmaceuticals USA
2006-10 – 2006-10 · Healthy
What this study did
NCT00974441 · Teva Pharmaceuticals USA
2006-08 – 2006-09 · Healthy
What this study did
NCT00834990 · Teva Pharmaceuticals USA
2003-09 – 2003-09 · Healthy
What this study did
NCT00834639 · Teva Pharmaceuticals USA
2003-09 – 2003-09 · Healthy
What this study did
Phase 4 (1)
Bipolar Disorder
NCT00545675 · Korea Otsuka Pharmaceutical Co., Ltd.
2007-12 – 2010-07 · Bipolar Disorder
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Bipolar Disorder
NCT00063362 · University Hospitals Cleveland Medical Center
2002-02 – 2007-07 · Bipolar Disorder
What this study did
Other / comorbidity
NCT00868452 · Sumitomo Pharma America, Inc.
2009-04 – 2012-01 · Bipolar Depression
What this study did
Phase 4 (1)
Bipolar Disorder
NCT00402324 · Eli Lilly and Company
2006-12 – 2008-02 · Bipolar I Disorder
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Absence Seizures: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Divalproex Sodium (Depakote): this drugApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.